Live Breaking News & Updates on Prostate Cancer Imaging

Stay updated with breaking news from Prostate cancer imaging. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.

Privacy Policy , Prostate Cancer Imaging , Ealth Press Release ,

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil | Comunicados | Edición USA

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

United States , Porto Alegre , Rio Grande Do Sul , Rafael Madke , Stewart Holmstrom , Unitedstatesandmaynotbeofferedorsoldwithintheunited States , Produtos Farmac , Christian Behrenbruch , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Nuclear Medicine Innovation Vice , Brazilian Cancer Institute , Australian Therapeutic Goods Administration , Corporate Communications , European Union , Telix Pharmaceuticals Limited , Cdx The Company , Granted Use Authorisation , Prostate Cancer Imaging , Pharmaceuticals Limited , Brazilian Health Regulatory Agency , Agencia Nacional De Vigilancia Sanitaria , Managing Director , Innovation Vice President , Prostate Cancer ,

Australian TGA Approves Illuccix® for Prostate Cancer Imaging

Australian TGA Approves Illuccix® for Prostate Cancer Imaging
medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.

Privacy Policy , Telix Pharmaceuticals , Australian Therapeutic Goods Administration , Ga Approved , Prostate Cancer Imaging , Ealth Press Release ,

First Patient Dosed in Japanese Prostate Cancer Imaging

First Patient Dosed in Japanese Prostate Cancer Imaging Study
May 24, 2021 21:04 ET
| Source:
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited
North Melbourne, AUSTRALIA
MELBOURNE, Australia and KYOTO, Japan, May 25, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product TLX591-CDx (Illuccix
®, Kit for the preparation of
68Ga-PSMA-11 injection). The study is an academic collaboration between Telix and Kanazawa University.
The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan. The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of T ....

United States , Cdx Illuccix , Shintaro Nishimura , Stewart Holmstrom , Christian Behrenbruch , Kanazawa Advanced Medical Center Kadmedic , Telix Pharmaceuticals , Kanazawa University , Australian Securities Exchange , Innovative Clinical Research Center , Australian Therapeutic Goods Administration , European Union , Corporate Communications , Telix Pharmaceuticals Limited , Nuclear Medicine At Kanazawa University Hospital , Kanazawa University Hospital , Pharmaceuticals Limited , Principal Investigator , Professor Mizokami , Professor Murayama , Professor Kinuya , Nuclear Medicine , Kanazawa Advanced Medical Center , Japan President , Molecularly Targeted Radiation , Australian Stock Exchange Tlx Ax ,

Czech Republic First European Country to Grant National Authorisation for the Use of Telix's Prostate Cancer Imaging Product Australian Stock Exchange:TLX.AX

Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
February 16, 2021 01:05 ET
| Source:
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited
North Melbourne, AUSTRALIA
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorisation allowing the use of TLX591-CDx (Kit for the preparation of
68Ga-PSMA-11), a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron Emission Tomography (PET). ....

United States , New Zealand , Czech Republic , Stewart Holmstrom , David Zogala , Christian Behrenbruch , Telix Pharmaceuticals , Czech Ministry Of Health , Nuclear Medicine Institute , University Hospital Prague , Australian Securities Exchange , Czech Society Of Nuclear Medicine , Treatment Programme , European Union , Corporate Communications , Telix Pharmaceuticals Limited , Ministry Of Health The Czech Republic , Therapeutic Goods Administration , Therapeutic Programme , Pharmaceuticals Limited , Prostate Specific Membrane Antigen , Positron Emission Tomography , Specific Therapeutic Programme , Czech Society , Nuclear Medicine , General University Hospital Prague ,